Reach the investors backing rounds like this
Backed by Advent Life Sciences, British Business Bank +6 more · verified emails and LinkedIn on Datapile
T-Therapeutics Raises $133 Million In Series B Funding To Advance Cancer And Autoimmune Disease Treatments - Pulse 2.0
T-Therapeutics is a biotechnology company developing next-generation T cell receptor (TCR) T cell engager (TCE) therapeutics for cancer and autoimmune diseases. They have raised $133 million in Series B funding to advance their first-in-class TCR-CD3 bispecific programs through clinical proof-of-concept. The company's proprietary OpTiMus® platform enables access to previously undruggable intracellular targets.
T-Therapeutics Raises $133 Million In Series B Funding To Advance Cancer And Autoimmune Disease Treatments Pulse 2.0
| Nov 11, 2026 | Zodia Custody | $67.0M | Series A | United Kingdom |
| Nov 10, 2026 | Monzo | $630.0M | — | United Kingdom |
| Nov 10, 2026 | Neobe | $6.1M | — | United Kingdom |
| Nov 05, 2026 | Revolut | $115.00B | — | United Kingdom |
You just read who funded T-Therapeutics. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.
Free account: 15 investor contact unlocks a month, no card required.